Monoclonal antibody products targeting IL-17 and/or IL-17R has have been approved for the treatment of immune-mediated diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [17]. This evidence concerns the gene IL17A and psoriasis.